Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseMyelodysplastic neoplasia 5q-SubgroupICD10D46.6MeSHSequenceChemotherapyChemo-substanceLenalidomideChemo-substanceLenalidomideChemo-substanceLenalidomideChemo-substanceLenalidomideNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlEmetogenicity (MASCC/ESMO)Febrile NeutropeniaInfectionsNeutropeniaThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorFenaux PDiseaseNiedrig- oder Intermediär-1-Risiko, singuläre Deletion am Chromosom 5, transfusionspflichtige AnämieOriginHopital Avicenne, Assistance Publique-Hôpitaux de Paris, Université Paris XIII, Bobigny, FranceProtocols in Revision 1 protocol foundProtocols under revision.Lenalidomide 10, Myelodysplastic Syndrome 5q- (PID118)